All In MedTech

Device Trial Radar · NCT04452149

Algorithm Using LINQ Sensors for Evaluation And Treatment of Heart Failure

Last checked: Nov 21, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 826 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

826

Actual

Start

Sep 3, 2020

Primary completion

Jun 2, 2025

Study completion Jun 2, 2025

Sponsor

Sponsor type
Industry
First posted
Jun 30, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ALLEVIATE-HF study is a prospective, randomized, controlled, blinded, multi-site, interventional, investigational device exemption (IDE) pivotal study. The purpose of the study is to demonstrate the safety and efficacy of a patient management pathway that utilizes an integrated device diagnostic-based risk stratification algorithm to guide patient care in subjects with NYHA class II and III heart failure, and to demonstrate the safety of the Reveal LINQ™ system and procedure in the study population.

Conditions

  • Heart Failure NYHA Class II
  • Heart Failure NYHA Class III

Interventions

  • Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware downloadDevice

    Reveal LINQ™ Insertable Cardiac Monitor with investigational ALLEVIATE-HF RAMware download.

  • Medication interventionOther

    Risk status guided medication intervention.

  • Not Randomized to Device or Medication InterventionOther

    No intervention was assigned due to not being randomized under the final version of the investigational plan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of Patient Management Pathway - Proportion of PRN Medication Interventions With Associated PRN Medication Intervention Related Serious Adverse Events (SAEs)Time frame: From 6 weeks after installation of RAMware through the duration of follow-up for Intervention arm subjects, and from the conclusion of the 13-month randomized period through the duration of follow-up for Observation arm subjects, up to 3 years.

1 more outcomes with a free account

Locations

53 sites in 1 country. Site status is shown where the registry gives one.

  • Cardiovascular Associates of Mesa

    Mesa, Arizona

52 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.